Day: January 4, 2021

LA JOLLA, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) — Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or “Company”) today announced that Michelle Johnson has been promoted to Chief Talent & Diversity Officer, effective immediately. Ms. Johnson was previously Senior Vice President of People & Talent, having served in this role since joining the Company in 2019.“I am excited to see Michelle ascend into this newly created role as Palomar continues to build an agile and innovative workplace grounded in ethical behavior and inclusivity,” commented Mac Armstrong, Chairman and Chief Executive Officer. “Since joining Palomar, Michelle has demonstrated a stellar aptitude for cultivating and expanding a dynamic workforce for our growing Company. In this new role, Michelle will continue to oversee our talent strategies and programs...

MORRISVILLE, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 8:20 a.m. EST.A live webcast of the event, along with a link to the presentation materials and archived audio replay of the presentation, will be available on the Company’s Investor Relations website at investor.syneoshealth.com.About Syneos HealthSyneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial...

Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients.A single dose of 3.0 mg/kg of ATYR1923 resulted in a median time to recovery of 5.5 days.83% of patients receiving 3.0 mg/kg dose of ATYR1923 achieved recovery in less than a week.Management to host conference call and webcast today, January 4, at 5:00pm ET/2:00pm PT.SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced positive topline results from its Phase 2 double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do not require mechanical ventilation. The trial met...

WESTPORT, Conn., Jan. 04, 2021 (GLOBE NEWSWIRE) — Compass Diversified (NYSE: CODI) (“CODI” or the Company”), an owner of leading middle market businesses, announced today that its Board of Directors (the “Board”) has declared a quarterly cash distribution of $0.36 per share on the Company’s common shares (the “Common Shares”). The distribution for the three months ended December 31, 2020 is payable on January 22, 2021 to all holders of record of Common Shares as of January 15, 2021.The Board also declared a quarterly cash distribution of $0.453125 per share on the Company’s 7.250% Series A Preferred Shares (the “Series A Preferred Shares”). The distribution on the Series A Preferred Shares covers the period from, and including, October 30, 2020, up to, but excluding, January 30, 2021. The distribution for such period is payable...

HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 4:30 p.m. Eastern Time.A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.About KiniksaKiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated...

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference being held from January 11 – 14, 2021. A webcast of the on-demand presentation will be available on the investor section of the Genocea website at http://ir.genocea.com, beginning on Monday, January 11, 2021.Following the conclusion of the conference, the presentation will remain archived on the Genocea website for approximately 90 days.About Genocea Biosciences, Inc.Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform...

NEWTON, Kan., Jan. 04, 2021 (GLOBE NEWSWIRE) — Park Aerospace Corp. (NYSE – PKE) announced that it plans to release its financial results for its 2021 fiscal year third quarter ended November 29, 2020 before the New York Stock Exchange opens on Thursday, January 7, 2021. The Company will conduct a conference call to discuss such results at 11:00 a.m. EST on the same day. Forward-looking and other material information may be discussed in this conference call. The conference call dial-in number is 844-466-4114 in the United States and Canada and 765-507-2654 in other countries and the required passcode is 4883755.A live audio webcast, along with presentation materials, will be available at https://edge.media-server.com/mmc/p/fpex6v6n 11:00 a.m. EST on Thursday, January 7, 2021. The presentation materials will also be available...

WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced a public offering of 1,750,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (“SEC”). All shares of common stock to be sold in the offering will be sold by Prelude. In addition, Prelude expects to grant the underwriters a 30-day option to purchase up to an additional 262,500 shares of common stock at the public offering price, less underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Morgan Stanley, Goldman Sachs & Co. LLC,...